Objectives-To validate a provocative chelation test with 2,3-dimercaptosuccinic acid (DMSA) by direct comparison with the standard ethylene diamine tetraacetic acid (EDTA) test in the same subjects; and to compare and contrast the predictors of lead excretion after DMSA with those after EDTA. A metal chelating agent given orally, DMSA may mobilise and enhance the excretion of lead from the storage sites in the body that are most directly relevant to the health effects of lead. A provocative chelation test with DMSA could thus have wide potential application in clinical care and epidemiological studies. Methods-34 male lead workers in the Republic of Korea were given a single oral dose of 10 mglkg DMSA, urine was collected over the next eight to 24 hours, and urine volume and urinary lead concentration determined at 0, 2, 4, 6, 8, and 24 hours. Either two weeks before or two weeks after the dose of DMSA 17 of these workers also received 1 g intravenous EDTA followed by an eight hour urine collection with fractionation at 0, 2, 4, 6, and 8 hours.
Results-Urinary lead concentration peaked at two hours after DMSA and four hours after EDTA. Lead excretion after DMSA was less than after EDTA, and cumulative excretion after DMSA plateaued at six to eight hours. The two hour and four hour cumulative lead excretions after DMSA were highly correlated with the eight hour total (r = 0-76 and 0.95). In multiple linear regression analyses, blood lead was found to be an important predictor of EDTA-chelatable lead, whereas urinary aminolevulinic acid (ALAU) was associated with DMSAchelatable lead. Notably, lead excretion after DMSA was greatly increased if EDTA was given first. An earlier dose of EDTA also modified the relation between ALAU and DMSA-chelatable lead in that workers who received EDTA before DMSA showed a much steeper doseresponse relation between these two measures.
Conclusions-The predictors of lead excretion after DMSA and EDTA are different and an earlier dose of EDTA may increase lead excretion after a subsequent dose of DMSA. The results suggest that two hour or four hour cumulative lead excretion after DMSA may provide an estimate of lead in storage sites that are most directly relevant to the health effects of lead.
(Occup Environ Med 1995;52: [13] [14] [15] [16] [17] [18] [19] Keywords: chelating agents; dimercaptosuccinic acid; lead Human exposure to lead is ubiquitous and its absorption can be assessed by different measures thought to reflect several definable lead storage compartments.'-3 Blood lead and zinc protoporphyrin (ZPP) are the two most common measures used to identify people at risk of excess exposure or ill health caused by lead. A limitation of both of these measures is that they are poor predictors of such ill health, do not necessarily reflect recent exposure, and are generally thought to be inadequate measures of cumulative lead absorption. 4 Blood lead concentrations are influenced by recent exposure, bioavailable internal stores, and differences between individuals in lead toxicokinetics. 5 The interpretation of ZPP, an early biological intermediary in the haematopoietic system, is complicated by differences between people in the kinetics of lead, the kinetics of the multiple steps in the haem synthetic pathway, and the kinetics of red blood cells. 5 The limitations of blood lead and ZPP have led to the development of other biological measures of lead absorption. As 90-95% of the total body burden of lead resides in bone,' in at least two definable compartments-a relatively inert cortical bone storage pool and a more bioavailable pool in trabecular bone-x ray fluorescence has emerged as a technique for measurement of bone lead.7-'0 Although x ray fluorescence of cortical bone lead probably best estimates cumulative lead absorption, few studies have validated this as a predictor of health effects. It can be hypothesised that because much of the bone lead compartment is biologically inert, with lead deep in cortical bone, x ray fluorescent measurements of cortical bone lead may be less relevant to long term changes in health than biological measures that estimate the bioavailable lead pool. Such measures may include x ray fluorescence of trabecular bone lead and chelatable lead.
Provocative chelation with 1 g of intra-lead has long been used to estimate the chelatable lead burden, thought to be one estimate of the bioavailable lead pool. Several studies have found that EDTA-chelatable lead correlated with renal dysfunction," 14 neurobehavioral dysfunction,' or declines in function of the peripheral nervous system.'6 No studies have directly compared measures of cumulative lead exposure, blood lead, cortical bone lead, trabecular bone lead, and chelatable lead as predictors of health effects related to lead. It is thus not possible to conclude whether EDTA-chelatable lead is a better predictor of health effects than blood lead simply because it provides a better estimate of cumulative absorption. An obstacle to the large scale epidemiological use of EDTA-chelatable lead is that EDTA needs to be given intravenously followed by at least a six to eight hour urine collection. In contrast, 2,3-dimercaptosuccinic acid (DMSA; succimer, Chemet) is a chelating agent that is given orally and has several advantages compared with EDTA. Firstly, it is more specific for lead than EDTA, resulting in less loss of such important minerals as zinc. Secondly, in studies in animals it does not result in increased gastrointestinal absorption of lead or increased brain lead concentrations as has been reported with EDTA.'7 1 During therapeutic chelation DMSA is generally well tolerated with occasional gastrointestinal (nausea, diarrhoea) or dermatological (rash) side effects. A provocative chelation test with DMSA would be more convenient and logistically feasible for estimation of the chelatable lead pool. Although DMSA has been extensively used for the treatment of lead intoxication in children and adults,'9 21 no previous studies have directly compared lead excretion after a dose of EDTA with that after a dose of DMSA in humans, nor identified predictors of cumulative lead excretion after a single oral dose of DMSA in currently exposed lead workers. We present the results of such a study in general industrial lead workers in the Republic of Korea.
Materials and methods

STUDY POPULATION AND DESIGN
Study subjects were recruited from four factories that use lead in the Republic of Korea. Participation was voluntary. All 34 workers exposed to lead were men, with a mean (SD) age of 39-6 (9 8) years and a mean (SD) work duration of 7-1 (6-1) years. In this study, we were interested in identifying predictors of DMSA-chelatable lead as well as comparing lead excretion after a dose of EDTA to that after DMSA in the same subjects. Subjects were divided into two groups because of constraints on resources. A total of 17 workers from a single secondary smelting facility received DMSA followed by an eight hour urine collection (DMSA only group). An additional 17 workers each received DMSA and EDTA two weeks apart in randomised order. In these workers, urine was collected for 24 hours after DMSA and eight hours after EDTA (DMSA v EDTA group). These 17 workers were recruited from a lead storage battery factory (n = 5), a litharge manufacturing factory (n = 6), and a polyvinyl chloride stabiliser manufacturing factory (n = 6). Finally, five non-exposed men each received DMSA orally followed by a 24 hour urine collection. These subjects had a mean (SD) age of 32-2 (9 0) years and a mean blood lead concentration of [5] [6] [7] (1-3) pg/dl. The For statistical analyses of cumulative lead excretion, urinary lead concentration was adjusted for a standard urine specific gravity of 1-020. 23 Urinary lead concentrations after a dose of DMSA, adjusted for urine specific gravity, correlated highly with the unadjusted measures (r = 0-69, P < 0-00 1). After EDTA was given, the correlation of the adjusted and unadjusted urinary lead concentrations was lower (r = 0-39, P = 0-001 (table 1) . Non-exposed subjects all excreted <100 ug of lead in eight hours after DMSA, compared with a mean of 1369 ,ug for the 34 lead workers (table 1). In the 17 subjects who received both DMSA and EDTA, urinary lead excretion was always higher after EDTA, and the mean lead excretion eight hours after EDTA was almost three times higher than that after DMSA (table 1) . Although the mean cumulative lead excretion at 24 hours after DMSA had increased by an average of 36% above the eight hour total, the eight hour and 24 hour values were perfectly correlated (r = 1-00, P < 0-001, n = 14 subjects). Hereafter, only results with the eight hour values are reported.
There was no difference in age between the 17 subjects who received DMSA only and the 17 subjects who received both DMSA and EDTA (table 1) and work duration were higher in the EDTA group, whereas ALAU ant urinary lead were higher in the D! group (table 1) .
On average, urinary lead con( peaked at about two hours after DM four hours after EDTA (fig 1) . Ur concentrations decreased rapid DMSA, returning to baseline by no 24 hours. After EDTA, urinary lea( trations reached a higher peak and hours the mean urinary lead concern 17 workers was still over 10 times baseline concentration. Cumulat excretion after DMSA plateaued eight hours, whereas it was still increasing at eight hours after EDT Figure 1 shows that cumulative lead X (n = 17) after EDTA would begin to plateau at about A (n =34) l 0 hours. The duration of the urine collection after a chelating agent has been given can be an obstacle to the epidemiological use of these measures of chelatable lead. Notably, the two and four hour cumulative lead excretions after DMSA correlated highly with the eight hour total in the 34 subjects (r = 0-76 for two hour v eight hour and r = 0 95 for four hour v eight hour), which suggests that a two or four hour urine collection would be adequate to estimate DMSA-chelatable lead. The eight hour cumulative lead excretions after DMSA and EDTA showed a modest correlation (r = 20 25 0 44, P = 0-08, n = 17); this value increased to r = 0-83 (P < 0-001) after the removal of two outliers. One of these subjects, who had DMSA first, had an eight hour lead excretion epidemiological settings. The data suggest that DMSA and EDTA lead excretion correlated; that lead excretion after EDTA was generally higher than after DMSA; that peak urinary lead concentrations and return to baseline are attained more rapidly after DMSA than after EDTA; and that lead excretion after DMSA is rapid, such that cumulative lead excretion at 2, 4, 6, 8, and 24 hours were all highly correlated. Blood lead was an important predictor of lead excretion after EDTA whereas ALAU was an important predictor of lead excretion after DMSA. Age, work duration, subject weight, and baseline urinary lead concentration were not consistently associated with lead excretion after either DMSA or EDTA in adjusted analyses. Interestingly, cumulative lead excretion after DMSA was higher in workers who received EDTA two weeks before DMSA. Also, EDTA given before DMSA was an important modifier of the relation between ALAU and eight hour lead excretion after DMSA.
The DMSA only group and the DMSA v EDTA group were recruited from different work sites. The two groups had similar ages, blood lead concentrations (although a statistically significant difference was found, we do not think that the difference in blood lead concentrations was biologically important), baseline urinary lead concentrations, and ALAU, but the DMSA v EDTA group had higher mean ZPP concentrations and work durations. We do not think, however, that uncontrolled confounding by work site is likely to have influenced the study results. When we controlled for these important measured confounding variables-that is, ones that we thought from the start were most likely to influence the relation between chelatable lead concentrations and the main independent variables such as blood lead and ALAU-there was no important change in the associations found. We thus think that it is unlikely that unmeasured confounders had a meaningful influence on these relations.
Although not entirely resolved,2526 DMSA Urinary excretion of altered DMSA, which consists of several oxidised species including mixed DMSA-cysteine disulphides, peaks at about four hours and is not complete for 24-48 hours.323' By 14 hours, about 21% of the DMSA given had appeared in the urine, with 88% as the altered form. Urinary lead excretion peaked at four hours and returned to baseline between six and eight hours. The DMSA is extensively bound to plasma proteins, mainly albumin, and does not seem to penetrate the erythrocytes." Although the structure of the DMSA-lead chelate is not currently known, some investigators hypothesised that the mixed DMSA-cysteine disulphides may be the active chelating species. 34 It is interesting to note that published cumulative excretion curves of unaltered DMSA are similar to those of cumulative lead excretion after DMSA in these Korean lead workers.
The DMSA-cysteine mixed disulphide has not been detected in blood but is the primary form of altered DMSA in urine."3 Plasma proteins may serve as a depot for DMSA in the blood. After transport to the kidney, exchange with cysteine may occur that results in excretion of the mixed disulphide. Although the biochemical basis for these transformations is not currently known, this suggests that DMSA may not be available in the blood for chelation of lead. Other data suggest that DMSA is primarily extracellular in its distribution." Lead may be chelated by DMSA just before excretion from the kidney. If DMSA only forms complexes with lead in the kidney just before excretion, this may also explain why DMSA does not cause redistribution of lead to soft tissue. The DMSA-chelatable lead may thus be very relevant to the epidemiological study of renal function and perhaps blood pressure.
Two workers, one of whom received DMSA first and the other EDTA first, excreted large quantities of lead after EDTA but small quantities after DMSA. It can be speculated that there could be differences between people in the formation of these 18 group.bmj.com on October 28, 2017 -Published by http://oem.bmj.com/ Downloaded from mixed disulphides, which are likely to be enzymatically mediated, and perhaps this could account for the relatively low excretion of lead in these two subjects after DMSA.
As DMSA itself seems to be mainly distributed in plasma and does not mobilise lead in bone, an important question is the interpretation of the DMSA provocative chelation test. Clearly, bone lead measured by x ray fluorescence is a better measure of cumulative lead absorption and retained body burden, but much of this lead is biologically inactive and x ray fluorescence is not widely available. The plasma compartment is thought to be very important to the health effects of lead in that all lead that is deposited in target organs passes through this compartment. Although whole blood lead concentrations were not a predictor of DMSA-chelatable lead, plasma lead concentrations may be, but measurement of plasma lead was beyond the scope of this study. The ultimate validation of DMSAchelatable lead awaits the results of prospective epidemiological studies.
